Previous 10 | Next 10 |
home / stock / mpsyf / mpsyf news
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. 2020 was a year of monumental progress in renewable energ...
The following slide deck was published by MorphoSys AG in conjunction with this event. For further details see: MorphoSys AG (MOR) Presents At 39th Annual J.P. Morgan Healthcare Conference - Slideshow
The following slide deck was published by MorphoSys AG in conjunction with this event. For further details see: MorphoSys AG (MOR) Investor Presentation - Slideshow
MorphoSys AG (MPSYF) Q3 2020 Earnings Call Transcript November 12, 2020 08:00 AM ET Company Participants Julia Neugebauer - Director, Investor Relations Jean-Paul Kress - Chief Executive Officer Roland Wandeler - Chief Operating Officer Malte Peters - Chief Research & Development Officer ...
MorphoSys AG (MOR) Q3 2020 Earnings Conference Call November 12, 2020, 08:00 AM ET Company Participants Julia Neugebauer - Director of IR Jean-Paul Kress - CEO Jens Holstein - CFO Malte Peters - Chief Research and Development Officer Roland Wandeler - COO Conference Call Participants Geoffrey...
The following slide deck was published by MorphoSys AG in conjunction with their 2020 Q3 earnings call. For further details see: MorphoSys AG 2020 Q3 - Results - Earnings Call Presentation
MorphoSys AG (MPSYF) announces that Jens Holstein steps down as the chief financial officer and board member, effective Dec. 31, 2020. Holstein says "...it is time for me to explore new opportunities.""Since joining in 2011, Jens' numerous contributions added substantially to making the ...
MorphoSys AG (MOR) Q2 2020 Earnings Conference Call August 06, 2020, 08:00 AM ET Company Participants Anja Pomrehn - Head of IR Jean-Paul Kress - CEO Jens Holstein - CFO Malte Peters - Chief Research and Development Officer Roland Wandeler - COO Conference Call Participant...
MorphoSys receives FDA approval for Monjuvi MorphoSys AG ( MOR ) announced that the FDA has approved the use of Monjuvi in conjunction with lenalidomide, for treating adult patients suffering from relapsed/refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, includ...
MorphoSys AG (MPSYF) Q1 2020 Earnings Conference Call May 7, 2020 8:00 AM ET Company Participants Julia Neugebauer - Director of IR Jean Kress - Chairman of Management Board, MD & CEO Jens Holstein - CFO & Member of the Management Board Malte Peters - Chief Research &a...
News, Short Squeeze, Breakout and More Instantly...
Morphosys Ag Ord Company Name:
MPSYF Stock Symbol:
OTCMKTS Market:
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 20, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG. Novartis BidCo Germany ...
Additional ASCO 2024 poster presentation will include new findings from the Phase 2 study of tulmimetostat PLANEGG and MUNICH, GERMANY / ACCESSWIRE / April 24, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that new efficacy and safety data from the Phase 3 MANIFEST-2 trial of pel...
Novartis offers € 68.00 per share in cash, representing a total equity value of € 2.7 billion Shareholders benefit from attractive premium of 94% and 142% on the volume-weighted average price during the last month and three months before January 25, 2024, respectively Acce...